Avian Enrofloxacin: Pharmacology, Clinical Use, and Resistance in Poultry

Introduction

Enrofloxacin is a synthetic fluoroquinolone antimicrobial agent developed exclusively for veterinary use. It exhibits broad-spectrum bactericidal activity against Gram-negative and Gram-positive bacteria, including members of the Enterobacteriaceae, Pasteurella spp., Mycoplasma spp., and certain intracellular pathogens [1, 2]. In poultry medicine, enrofloxacin is employed primarily for the treatment of respiratory and enteric infections, most notably colibacillosis caused by avian pathogenic Escherichia coli (APEC) and chronic respiratory disease associated with Mycoplasma gallisepticum [1, 3]. The drug acts by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby disrupting DNA replication and transcription [2, 4]. This mechanism of action is concentration-dependent, with the ratio of peak serum concentration to minimum inhibitory concentration (Cmax/MIC) and the area under the concentration-time curve to MIC (AUC/MIC) serving as primary pharmacodynamic indices [1, 2].

The clinical utility of avian enrofloxacin must be balanced against concerns regarding antimicrobial resistance (AMR) development and the persistence of drug residues in poultry tissues and the environment [5, 6, 7]. Regulatory frameworks in many jurisdictions mandate strict withdrawal periods to ensure food safety, and the detection of enrofloxacin residues in feathers has emerged as a novel monitoring tool [6, 8]. This article provides a detailed examination of the pharmacology, clinical applications, pharmacokinetic/pharmacodynamic (PK/PD) relationships, resistance mechanisms, and residue depletion profiles of enrofloxacin in poultry.

Pharmacology and Mechanism of Action

Enrofloxacin is a zwitterionic molecule with a piperazinyl ring at position C7 and a cyclopropyl group at N1, structural features that confer enhanced Gram-negative activity and tissue penetration [1, 4]. Following administration, enrofloxacin is partially de-ethylated to its primary active metabolite, ciprofloxacin, which itself possesses potent antimicrobial activity [9, 1]. The parent drug and its metabolite act synergistically against susceptible pathogens.

The bactericidal effect of enrofloxacin results from the stabilization of the DNA-gyrase complex, leading to double-strand DNA breaks and subsequent bacterial cell death [2, 4]. At therapeutic concentrations, enrofloxacin also induces oxidative stress within bacterial cells, contributing to its lethal action [4]. In eukaryotic cells, enrofloxacin has been shown to induce mitochondrial pathway apoptosis in poultry tissues, a finding relevant to the safety profile of the drug [4]. This pro-apoptotic effect is mediated through the activation of caspase cascades and the release of cytochrome c from mitochondria [4].

Pharmacokinetics in Poultry

The pharmacokinetic behavior of enrofloxacin in poultry is characterized by rapid absorption, extensive tissue distribution, and a relatively long elimination half-life [9, 1]. After oral administration in broiler chickens, enrofloxacin achieves peak plasma concentrations within 1 to 3 hours, with bioavailability exceeding 60% [1]. The drug is highly lipophilic, enabling penetration into the respiratory tract, reproductive organs, and skeletal muscle [9, 1].

A comprehensive study across five chicken breeds demonstrated significant breed-related differences in enrofloxacin residue depletion kinetics [9]. These differences are attributable to variations in hepatic cytochrome P450 activity, renal clearance, and body fat composition [9]. Monte Carlo simulations based on PK/PD data have been used to optimize dosing regimens for the treatment of colibacillosis in broilers, with target AUC/MIC ratios of 100 to 125 being predictive of clinical efficacy [1].

Tissue distribution studies reveal that enrofloxacin accumulates in feathers, where residues persist for extended periods [6, 8]. Quantitative UHPLC-MS/MS detection methods have confirmed the presence of enrofloxacin and ciprofloxacin in feathers of broiler parent stock long after the cessation of treatment [6]. This finding has implications for both food safety monitoring and the non-invasive assessment of historical antimicrobial exposure [6, 8].

Table 1: Key Pharmacokinetic Parameters of Enrofloxacin in Broiler Chickens

Clinical Indications and Therapeutic Use

Avian enrofloxacin is indicated for the treatment of infections caused by susceptible bacterial pathogens in chickens, turkeys, and other poultry species. The primary clinical indications include colibacillosis, mycoplasmosis, fowl cholera (caused by Pasteurella multocida), and secondary bacterial infections complicating viral respiratory diseases [1, 3].

Colibacillosis

Colibacillosis, caused by APEC, is one of the most economically significant bacterial diseases in poultry [1]. Enrofloxacin is frequently employed for the treatment of systemic colibacillosis, including airsacculitis, pericarditis, and perihepatitis [1]. PK/PD modeling and Monte Carlo simulations have established that enrofloxacin administered at 10 mg/kg body weight orally once daily achieves target attainment rates exceeding 90% against APEC isolates with MIC values at or below 0.125 µg/mL [1].

Respiratory Infections

Enrofloxacin is used to manage respiratory infections in poultry, including those associated with Mycoplasma gallisepticum, Ornithobacterium rhinotracheale, and Pasteurella multocida [3]. In a study evaluating the effect of enrofloxacin on broilers challenged with H9N2 avian influenza virus and infectious bronchitis virus, enrofloxacin treatment improved clinical parameters and mucociliary clearance, although it did not eliminate the viral pathogens [3]. This highlights the role of enrofloxacin in controlling secondary bacterial infections during viral respiratory outbreaks [3].

Combination Therapy

Research has explored the interaction between enrofloxacin and natural compounds to enhance efficacy and reduce resistance selection. The flavonoid morin has been shown to potentiate enrofloxacin bioavailability through inhibition of ABC transporters and to provide hepatoprotective effects via antioxidant pathway activation [10]. Additionally, essential oils from cinnamon bark, clove bud, and lavender flower have demonstrated synergistic activity with enrofloxacin against multidrug-resistant E. coli strains isolated from broiler chicks [11]. These combination strategies may reduce the effective dose of enrofloxacin required, thereby mitigating selection pressure for resistance [10, 11].

Antimicrobial Resistance

The emergence of resistance to enrofloxacin in poultry pathogens is a growing concern. Resistance mechanisms include target site mutations in DNA gyrase (gyrA and gyrB genes) and topoisomerase IV (parC and parE genes), reduced drug accumulation through efflux pump overexpression, and plasmid-mediated quinolone resistance (PMQR) determinants such as qnr genes [7, 11].

Selection at Sub-ECOFF Concentrations

A critical finding in resistance ecology is that enrofloxacin can select for resistant E. coli at concentrations lower than the epidemiological cutoff value (ECOFF) [7]. In broiler-derived cecal fermentation models, exposure to subinhibitory concentrations of enrofloxacin enriched for resistant populations, including those cross-resistant to amoxicillin and doxycycline [7]. This phenomenon underscores the risk of resistance emergence even when drug concentrations fall below the MIC of susceptible populations [7].

Environmental Dissemination

Enrofloxacin and its active metabolite ciprofloxacin persist in poultry litter and droppings, contributing to the environmental reservoir of antimicrobial residues [5]. This persistence facilitates the selection of resistant bacteria in the farm environment and may promote the horizontal transfer of resistance genes among bacterial populations [5]. The role of litter as a hidden driver of AMR emergence has been emphasized in recent studies [5].

Resistance in Key Pathogens

Resistance to enrofloxacin has been documented in E. coli, Klebsiella pneumoniae, and Pasteurella multocida isolates from poultry [7, 2, 11]. In a study using an in vivo infection model in young chicks, the PK/PD relationships of enrofloxacin against K. pneumoniae were characterized, with the AUC/MIC ratio being the best predictor of efficacy [2]. The emergence of multidrug-resistant strains, including those resistant to enrofloxacin, complicates therapeutic management and necessitates the development of alternative strategies [11].

Residue Depletion and Food Safety

Regulatory authorities have established maximum residue limits (MRLs) for enrofloxacin in poultry tissues, including muscle, liver, kidney, and skin with fat [9, 6]. Compliance with withdrawal periods is essential to prevent violative residues in poultry products intended for human consumption.

Tissue Residue Depletion

Residue depletion studies have demonstrated that enrofloxacin and ciprofloxacin concentrations decline rapidly in muscle and liver following the cessation of treatment, but persist longer in feathers and skin [9, 6, 8]. Breed-specific differences in depletion kinetics have been observed, with some breeds exhibiting slower clearance [9]. These differences may be related to genetic polymorphisms in drug-metabolizing enzymes [9].

Feather Residues as a Monitoring Tool

The detection of enrofloxacin residues in feathers has emerged as a sensitive and non-invasive method for monitoring historical antimicrobial use in poultry [6, 8]. UHPLC-MS/MS analysis of feather samples can detect enrofloxacin and flumequine residues weeks to months after treatment [8]. This approach has been applied to broiler parent stock, revealing continued presence of residues in feathers long after the withdrawal period [6]. Feather analysis may serve as a valuable tool for auditing antimicrobial use in poultry production systems [6, 8].

Analytical Detection Methods

Several analytical methods have been developed for the detection of enrofloxacin residues in poultry tissues. A microbial inhibition assay using Bacillus licheniformis in a microplate format has been validated for the detection of enrofloxacin and sulfamethazine in spiked chicken kidney, liver, and muscle tissues [12]. This assay offers a cost-effective screening alternative to instrumental methods such as HPLC and LC-MS/MS [12].

Diagnostic Considerations

Diagnosis of bacterial infections in poultry requires isolation and identification of the causative agent, followed by antimicrobial susceptibility testing. For enrofloxacin, determination of the MIC is essential for guiding therapy and monitoring resistance trends [1, 2]. Molecular methods, including PCR and sequencing of gyrA and parC genes, can detect resistance-associated mutations [7, 11].

Table 2: Common Bacterial Pathogens in Poultry and Enrofloxacin Susceptibility

Control and Prevention Strategies

Control of bacterial diseases in poultry relies on a combination of biosecurity, vaccination, and judicious antimicrobial use. For enrofloxacin, the following strategies are recommended to preserve its efficacy:

1. Targeted therapy: Use enrofloxacin only when bacterial culture and susceptibility testing confirm susceptibility [1, 2].
2. Optimized dosing: Employ PK/PD-guided dosing regimens to achieve therapeutic concentrations while minimizing selection for resistance [1, 2].
3. Combination therapy: Consider synergistic combinations with essential oils or other agents to reduce the required dose [10, 11].
4. Resistance surveillance: Implement routine monitoring of enrofloxacin MICs in key pathogens to detect emerging resistance [7, 11].
5. Environmental management: Manage litter and droppings to reduce the environmental reservoir of residues and resistant bacteria [5].

Mermaid Diagram: Decision Tree for Enrofloxacin Use in Poultry Colibacillosis

flowchart TD
    A[Clinical signs of colibacillosis], > B[Collect samples for culture and AST]
    B, > C{Isolate E. coli?}
    C, >|Yes| D[Perform MIC testing for enrofloxacin]
    C, >|No| E[Consider alternative diagnoses]
    D, > F{MIC <= 0.125 µg/mL?}
    F, >|Yes| G[Initiate enrofloxacin therapy at 10 mg/kg PO q24h]
    F, >|No| H[Select alternative antimicrobial]
    G, > I[Monitor clinical response at 48-72 h]
    I, > J{Clinical improvement?}
    J, >|Yes| K[Complete 5-day course]
    J, >|No| L[Re-culture and re-evaluate susceptibility]
    K, > M[Adhere to withdrawal period]
    M, > N[Monitor for residues in feathers/tissues]

Safety and Adverse Effects

Enrofloxacin is generally well tolerated in poultry at therapeutic doses. However, safety concerns include the potential for arthropathy in rapidly growing birds, although this is less pronounced in poultry than in juvenile mammals [4]. The induction of mitochondrial apoptosis in poultry tissues has been documented, raising questions about cellular safety at high doses or prolonged exposure [4]. Hepatoprotective agents such as morin may mitigate some of these effects [10].

Conclusion

Avian enrofloxacin remains a valuable antimicrobial for the treatment of bacterial infections in poultry, particularly colibacillosis and respiratory diseases. Its clinical efficacy is supported by robust PK/PD data, and emerging strategies such as combination therapy with natural compounds may enhance its utility. However, the selection and dissemination of resistance, coupled with the persistence of residues in feathers and the environment, necessitate careful stewardship. Ongoing surveillance of resistance patterns, adherence to withdrawal periods, and implementation of integrated disease control measures are essential to preserve the effectiveness of enrofloxacin in poultry medicine.

References

[1] Felix LA, Egito BM, David DD, et al. Pharmacokinetics, pharmacodynamic efficacy prediction indices, and Monte Carlo simulations of enrofloxacin for the treatment of colibacillosis in broiler chickens. Open Vet J. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41200291/

[2] Wei Y, Li Y, Zhao H, et al. Pharmacokinetic/pharmacodynamic relationships of enrofloxacin against Klebsiella pneumoniae in an in vivo infection model in young chicks. Poult Sci. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38833743/

[3] Abbasnia M, Mosleh N, Dadras H, et al. Effect of enrofloxacin on clinical parameters and mucociliary system of broilers challenged with H9N2 avian influenza/infectious bronchitis viruses. Vet Med Sci. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38419286/

[4] Grabowski Ł, Choszcz M, Wiśniewska K, et al. Induction of the mitochondrial pathway of apoptosis by enrofloxacin in the context of the safety issue of its use in poultry. Apoptosis. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38281280/

[5] Vargas MB, Nettle C, Soto I, et al. Persistence and Dissemination of Enrofloxacin and Ciprofloxacin Residues: The Hidden Role of Litter and Droppings in the Emergence of Antimicrobial Resistance. Animals (Basel). 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41594521/

[6] Ringenier M, Cherlet M, Dewulf J, et al. Continued presence of enrofloxacin residues in feathers of broiler parent stock based on quantitative UHPLC-MS/MS detection. Poult Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40187010/

[7] Swinkels AF, Fischer EAJ, Korving L, et al. Selection for amoxicillin-, doxycycline-, and enrofloxacin-resistant Escherichia coli at concentrations lower than the ECOFF in broiler-derived cecal fermentations. Microbiol Spectr. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39269186/

[8] Ringenier M, Cherlet M, Dewulf J, et al. Residue depletion of enrofloxacin and flumequine in feathers of broilers based on quantitative UHPLC-MS/MS detection. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38935119/

[9] Chen D, Wang C, Liu Y, et al. A comprehensive study on enrofloxacin residue depletion in five chicken breeds. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42056824/

[10] Deng H, Kong Q, Gao Y, et al. Dual mechanisms of morin in bioavailability potentiation and hepatoprotection: Enhancing enrofloxacin safety in poultry through ABC transporter inhibition and antioxidant pathway activation. Vet J. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41887316/

[11] Zych S, Adaszyńska-Skwirzyńska M, Szewczuk MA, et al. Interaction between Enrofloxacin and Three Essential Oils (Cinnamon Bark, Clove Bud and Lavender Flower)-A Study on Multidrug-Resistant Escherichia coli Strains Isolated from 1-Day-Old Broiler Chickens. Int J Mol Sci. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38791259/

[12] Mirzaie S, Jamiri F, Javanmard Dakheli M, et al. A microbial inhibition assay in microplates using Bacillus licheniformis for detection of enrofloxacin and sulfamethazine in chicken spiked kidney, liver and muscle tissues. Vet Med Sci. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37791987/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.